Details for Patent: 7,176,220
✉ Email this page to a colleague
Which drugs does patent 7,176,220 protect, and when does it expire?
Patent 7,176,220 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.
Protection for GENVOYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-six patent family members in thirty-two countries.
Summary for Patent: 7,176,220
Title: | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Abstract: | An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human. |
Inventor(s): | Satoh; Motohide (Takatsuki, JP), Kawakami; Hiroshi (Takatsuki, JP), Itoh; Yoshiharu (Takatsuki, JP), Shinkai; Hisashi (Takatsuki, JP), Motomura; Takahisa (Takatsuki, JP), Aramaki; Hisateru (Takatsuki, JP), Matsuzaki; Yuji (Takatsuki, JP), Watanabe; Wataru (Takatsuki, JP), Wamaki; Shuichi (Takatsuki, JP) |
Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
Application Number: | 10/492,833 |
Patent Claim Types: see list of patent claims | Use; Compound; Composition; |
Drugs Protected by US Patent 7,176,220
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-001 | Sep 24, 2014 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,176,220
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2002-336843 | Nov 20, 2002 |
Japan | 2003-065807 | Mar 11, 2003 |
Japan | 2003-139616 | May 16, 2003 |
PCT Information | |||
PCT Filed | November 20, 2003 | PCT Application Number: | PCT/JP03/14773 |
PCT Publication Date: | June 03, 2004 | PCT Publication Number: | WO2004/046115 |
International Family Members for US Patent 7,176,220
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 042095 | ⤷ Try a Trial | |||
Argentina | 087046 | ⤷ Try a Trial | |||
Austria | 443048 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |